AbbVie looks to shed Allergan's legacy women's health unit as it hunkers down for Humira biosim doomsday — report

With the clock ticking on its blockbuster Humira patent in the US, AbbVie is reportedly in talks to sell the $5 billion women’s health portfolio it acquired from Allergan in order to pay off debt and focus on new areas.